Aug 27, 2025
ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
Aug 12, 2025
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Aug 05, 2025
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
Aug 01, 2025
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Jul 01, 2025
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
Jun 16, 2025
ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
May 14, 2025
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
Mar 27, 2025
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
Mar 25, 2025
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
Mar 20, 2025
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
Jan 30, 2025
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Dec 30, 2024
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
Dec 11, 2024
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Dec 09, 2024
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
Dec 02, 2024
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Nov 07, 2024
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
Nov 05, 2024
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
Dec 15, 2020
ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures